Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- Conditions
- Acute Promyelocytic Leukemia
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 135
- Registration Number
- NCT02688140
- Locations
- 🇩🇪
OSHO study group, Multiple Locations, Germany
🇩🇪SAL study group, Multiple Locations, Germany
🇳🇱HOVON study group, Multiple Locations, Netherlands
Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL
- Conditions
- Leukaemia,Lymphoblastic
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT02660762
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
- Conditions
- Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
- Interventions
- Drug: Aracytine (Ara C)Drug: Granulocyte Colony-Stimulating Factor (G-CSF)Drug: Depomedrol
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 265
- Registration Number
- NCT02611492
- Locations
- 🇫🇷
Hopital Saint Louis, Paris, France
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02553460
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Rady Children's Hospital and Health Center, San Diego, California, United States
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Conditions
- Acute,Leukemia, Lymphoid
- Interventions
- Procedure: allogeneic hematopoietic stem cell transplantationProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2022-08-03
- Target Recruit Count
- 30
- Registration Number
- NCT02523976
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Leukemia, B-CellLymphoma, Non-Hodgkin'sAcute Lymphoblastic LeukemiaLeukemia, T-Cell
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT02518750
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
- Conditions
- Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRecurrent Ph-Like Acute Lymphoblastic LeukemiaRefractory Ph-Like Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02420717
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
- Conditions
- Acute Lymphoid LeukemiaAcute Myeloid LeukemiaMixed Lineage Acute Leukemia
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02419755
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Precursor-B Acute Lymphoblastic LeukemiaLymphoblastic LymphomaLymphomaLeukemia
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02419469
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator
- Conditions
- Inflammatory Bowel DiseaseUlcerative ColitisCrohn's Disease
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 3
- Registration Number
- NCT02413047
- Locations
- 🇺🇸
Indiana University Hospital, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.